#USA #New York #Pomerantz #Fractyl Health #GUTS

Pomerantz Law Firm Faces Fractyl Health Class Action

The notable Pomerantz Law Firm has announced the initiation of a class action lawsuit against Fractyl Health, Inc., a company publicly traded under the ticker symbol NASDAQ: GUTS. The lawsuit has been registered in the United States District Court for the Southern District of New York under the case number 26-cv-07167.

This legal action represents a collective effort to recover damages for investors who purchased or acquired securities of Fractyl Health between January 13, 2025, and January 29, 2026. The plaintiffs in this case are alleging that the company and certain of its officers have breached federal securities laws. The objective is to seek remedies under important sections of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a), along with Rule 10b-5.

If you bought shares of Fractyl during the stated period, it is crucial to act quickly as you have until October 20, 2026, to request the Court to appoint you as Lead Plaintiff for the affected class. Investors seeking further information can access a copy of the Complaint on Pomerantz's official website, www.pomerantzlaw.com, or reach out directly to Danielle Peyton for discussions surrounding this lawsuit.

Background on Fractyl Health

Fractyl Health is a medical biotechnology company focused on developing therapies aimed at treating type 2 diabetes and obesity. One of their flagship developments is the Revita DMR System, designed to provide outpatient procedural therapy that targets duodenal dysfunction, a common complication arising from high-fat and high-sugar dietary habits.

During the specified Class Period, Fractyl Health emphasized advancing the Revita project through its REMAIN-1 clinical study, which aims to investigate the long-term effectiveness of Revita in maintaining weight loss after discontinuing GLP-1 receptor agonist drug therapy. This study encompasses three different patient groups: REVEAL-1, REMAIN-1 Midpoint, and REMAIN-1 Pivotal Cohorts.

Despite the company's efforts to showcase Revita's benefits using interim data from these cohorts, the reality has proven to be more complex. Fractyl's management, including CEO Harith Rajagopalan, has been quoted making bold claims about the therapy's efficacy, designating the data as